Cancer is the disease that’s characterized by uncontrolled cell growth. In some cases, cancer can metastasize i.e. spread to other parts of the body. Cancer is the deadliest disease and requires immediate attention of doctor. Despite of availability of number of anticancer drugs (oncology drugs), a lot is left to be discovered.

Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer. Alkem has dedicated division for anticancer products, which is christened ‘Cytomed Division’. Cytomed division has been in existence for over 17 years. As far as anticancer medicines are concerned, Alkem Cytomed has hormonal preparations, cytotoxic drugs and targeted therapeutic drugs in the portfolio.

Alkem Cytomed offers three biosimilar drugs i.e. Rituximab (Cytomab), Bevacizumab (Advamab) and Trastuzumab (Hersima). All of these are monoclonal antibodies.

• Rituximab is highly recommended by oncologists as targeted therapy for treatment of one of the cancer Non-Hodgkin lymphoma (NHL) and autoimmune disorder like rheumatoid arthritis (RA).
• Bevacizumab  is used as a targeted therapy in advanced stages of Colorectal Cancer & Recurrent Ovarian Cancer.
• Trastuzumab is used as a targeted therapy in HER2 +ve Breast Cancer &  HER2 +ve Gastric Cancer

Enzene Biosciences, a dedicated research unit of Alkem Laboratories, is currently working on number of monoclonal antibodies. Also, there are several other biosimilar drugs that are in the pipeline.